Could an MS drug tame a rare Virus-Caused paralysis?

NCT ID NCT04799288

Recruiting now Disease control Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether teriflunomide, a drug already used for multiple sclerosis, can help people with a rare spinal cord disease called HAM/TSP caused by the HTLV-1 virus. About 24 adults will take the drug daily for 9 months to see if it reduces harmful immune activity and improves symptoms. The goal is to find a safe treatment for this progressive condition that currently has no approved therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAM/TSP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tropical spastic paraparesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAM/TSP

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••